EGFR and neoplasm: (103) showed that a large number of bystander CD39-CD8+ T cells in EGFR-mutated tumor cells led to poor reactions to ICIs, while the proportion of CD39+ CD8+ TILs was visibly higher in patients with wild-type EGFR.